IL-17 tailender UCB gets EU OK for bimekizumab in psoriasisUCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU Share XIL-17 tailender UCB gets EU OK for bimekizumab in psoriasishttps://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/
UCB’s bimekizumab ‘pre-approved’ using NICE fast-track schemeUCB’s bimekizumab hasn’t been approved for marketing in Europe yet, but has already been given the nod for Share XUCB’s bimekizumab ‘pre-approved’ using NICE fast-track schemehttps://pharmaphorum.com/news/ucbs-bimekizumab-pre-approved-using-nice-fast-track-scheme/
UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialBelgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, Share XUCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasis trialhttps://pharmaphorum.com/news/ucbs-il-17-latecomer-bimekizumab-beats-cosentyx-in-psoriasis-trial/
UCB posts more supportive data from Humira rival bimekizumabThere’s a whole gang of pharma companies queueing up to steal market share from AbbVie’s mega-blockbuster Humira, and Share XUCB posts more supportive data from Humira rival bimekizumabhttps://pharmaphorum.com/news/ucb-posts-more-supportive-data-from-humira-rival-bimekizumab/
UCB’s bimekizumab tops J&J’s Stelara in psoriasis studyThe first phase 3 data with UCB’s key pipeline drug bimekizumab show that it hit all its efficacy Share XUCB’s bimekizumab tops J&J’s Stelara in psoriasis studyhttps://pharmaphorum.com/news/ucbs-bimekizumab-tops-jjs-stelara-in-psoriasis-study/
